Skip to content
← All interventions
Senolytic candidate

Quercetin

Automated longevity evidence pipeline intervention.

Where the science stands

This page summarizes the current human evidence captured in the Longevity Compass database. Result interpretation is conservative and unresolved outcomes remain unknown.

Evidence depth 80 / 100

Research path

From biological idea to human evidence

These stages show different kinds of evidence for Quercetin. Moving through them does not mean an intervention is proven to slow aging.

  1. 1

    Biological idea

    Reviewing animal and laboratory research…

  2. 2

    Human testing

    17 direct aging trial links and 9 related trial links tracked. A trial count describes research activity, not benefit.

  3. 3

    What results show

    0 beneficial, 3 neutral and 0 harmful result links interpreted; 22 remain unresolved.

  4. 4

    Still unanswered

    Whether these findings translate into meaningful, lasting healthy-aging benefits in people remains unproven. Longer follow-up and clearer safety and clinical outcomes are needed.

How AgeBeacon evaluates evidence →

Beyond human trials

The bigger longevity story

Loading animal and laboratory evidence…

Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.

Signals we're watching

What human studies are measuring

Physical function

5 result(s) are linked, but direction remains unknown.

Muscle

1 result(s) are linked, but direction remains unknown.

Biological aging

0 beneficial, 1 neutral, 0 harmful and 0 mixed interpreted result(s); 5 remain unknown.

Cognition

8 result(s) are linked, but direction remains unknown.

Research depth

Human evidence picture

Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.

17
Direct aging trials
9
Indirect relevant trials
44
Publications linked
17
Results publications

Interpreted results

Beneficial
0
Neutral
3
Harmful
0
Unknown / unresolved
22

Population relevance

Healthy / aging
3
Disease-specific
3

Safety evidence

0

Trials currently identified with safety-result data.

Go to the source

Studies & publications

Inspect the original evidence behind this profile. Links open the trial registry, PubMed or the publication DOI.

Senolytics for Secondary Progressive MSNCT07270120INTERVENTIONAL · PHASE1 · 30 participants · NOT_YET_RECRUITINGSafety and Effectivness of Quercetin & Dasatinib on Epigenetic AgingNCT04946383INTERVENTIONAL · PHASE2 · 25 participants · UNKNOWNSenolytic Therapy to Modulate Progression of Alzheimer's DiseaseNCT04063124INTERVENTIONAL · PHASE1/PHASE2 · 5 participants · COMPLETEDStudy on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.NCT07466420INTERVENTIONAL · NA · 100 participants · RECRUITINGSenescence in Chronic Kidney DiseaseNCT02848131INTERVENTIONAL · PHASE2 · 30 participants · ENROLLING_BY_INVITATIONEvaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging EffectsNCT07678346INTERVENTIONAL · NA · 70 participants · NOT_YET_RECRUITINGEffects of Quercetin on Metabolic HealthNCT05297032INTERVENTIONAL · NA · 5 participants · TERMINATEDSenolytics to Improve Osteoporosis TherapyNCT06018467INTERVENTIONAL · PHASE2 · 120 participants · ACTIVE_NOT_RECRUITINGTargeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older HumansNCT04313634INTERVENTIONAL · PHASE2 · 74 participants · COMPLETEDEffects of a Dietary Supplement on Collagen Production and Evaluation of Its Regenerative and Anti-Ageing PropertiessNCT07521423INTERVENTIONAL · NA · 92 participants · COMPLETEDCombination Gerotherapeutic Interventions for Healthspan ImprovementNCT07475546INTERVENTIONAL · PHASE3 · 30 participants · ACTIVE_NOT_RECRUITINGVIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional SupplementsNCT04994561INTERVENTIONAL · PHASE1 · WITHDRAWNBian X, Snow ZK, Zinn CJ, Gowan CC, Conley SM, Bratulin AL, Elhusseiny KM, Miller J, Tchkonia T, Kirkland JL, Lerman LO, Hickson LJ. Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease. Kidney360. 2025 Mar 28;6(8):1278-1291. doi: 10.34067/KID.0000000776.PMID 40152935Results publicationHickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA, Khosla S, Koerber DM, Lagnado AB, Lawson DK, LeBrasseur NK, Lerman LO, McDonald KM, McKenzie TJ, Passos JF, Pignolo RJ, Pirtskhalava T, Saadiq IM, Schaefer KK, Textor SC, Victorelli SG, Volkman TL, Xue A, Wentworth MA, Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep;47:446-456. doi: 10.1016/j.ebiom.2019.08.069. Epub 2019 Sep 18.PMID 31542391Results publicationAndrews TD, Day GS, Irani SR, Kanekiyo T, Hickson LJ. Uremic Toxins, CKD, and Cognitive Dysfunction. J Am Soc Nephrol. 2025 Jun 1;36(6):1208-1226. doi: 10.1681/ASN.0000000675. Epub 2025 Feb 26.PMID 40009460Results publicationGarbarino VR, Palavicini JP, Melendez J, Barthelemy N, He Y, Kautz TF, Lopez-Cruzan M, Mathews JJ, Xu P, Zhan B, Saliba A, Ragi N, Sharma K, Craft S, Petersen RC, Espindola-Netto JM, Xue A, Tchkonia T, Kirkland JL, Seshadri S, Salardini A, Musi N, Bateman RJ, Gonzales MM, Orr ME. Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer's Disease. Res Sq [Preprint]. 2024 Mar 8:rs.3.rs-3994894. doi: 10.21203/rs.3.rs-3994894/v1.PMID 38496619Results publicationGonzales MM, Garbarino VR, Kautz TF, Palavicini JP, Lopez-Cruzan M, Dehkordi SK, Mathews JJ, Zare H, Xu P, Zhang B, Franklin C, Habes M, Craft S, Petersen RC, Tchkonia T, Kirkland JL, Salardini A, Seshadri S, Musi N, Orr ME. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med. 2023 Oct;29(10):2481-2488. doi: 10.1038/s41591-023-02543-w. Epub 2023 Sep 7.PMID 37679434Results publicationLili L, Smith S, Kunces L, Antonella R, Allegrini P, Togni S, Tongiani S, Rickard N, Readhead B, Phipps S, Zhang B. An Application of a Large-Scale, Data-Driven Approach to Prioritize Compound-Targeted Conditions in the Nutraceutical Space: Case Study of QuercefitTM (Quercetin Phytosome) Toward Unbalanced Lipid Conditions in Metabolically Challenged Adults. Mol Nutr Food Res. 2025 Nov;69(22):e70253. doi: 10.1002/mnfr.70253. Epub 2025 Sep 12.PMID 40936357Results publicationMillar CL, Iloputaife I, Baldyga K, Kuo J, Tchkonia T, Kirkland JL, Travison TG, Lipsitz LA. Rationale and Design of STAMINA: Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging, A Geroscience Feasibility Study. Transl Med Aging. 2023;7:109-117. doi: 10.1016/j.tma.2023.10.004. Epub 2023 Oct 21.PMID 40248131Results publicationSarkar P, Kumar A, Behera PS, Thirumurugan K. Phytotherapeutic targeting of the mitochondria in neurodegenerative disorders. Adv Protein Chem Struct Biol. 2023;136:415-455. doi: 10.1016/bs.apcsb.2023.02.013. Epub 2023 Mar 24.PMID 37437986Results publicationGonzales MM, Garbarino VR, Marques Zilli E, Petersen RC, Kirkland JL, Tchkonia T, Musi N, Seshadri S, Craft S, Orr ME. Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial. J Prev Alzheimers Dis. 2022;9(1):22-29. doi: 10.14283/jpad.2021.62.PMID 35098970Results publicationGonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME. A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mech Ageing Dev. 2021 Dec;200:111589. doi: 10.1016/j.mad.2021.111589. Epub 2021 Oct 21.PMID 34687726Results publicationGonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME. A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mech Ageing Dev. 2021 Dec;200:111589. doi: 10.1016/j.mad.2021.111589. Epub 2021 Oct 21.PMID 34687726Results publicationGuerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021 Sep;44(9):714-727. doi: 10.1016/j.tins.2021.06.007. Epub 2021 Aug 5.PMID 34366147Results publication

The big unanswered question

Can promising biology translate into meaningful healthy-aging benefits?

That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.

Confidence: moderateScore model: v0.5-curated-ruleUpdated: 2026-09-21Source: live evidence database